Valneva, Serum Institute Partner on Chikungunya Vaccine

Valneva SE has partnered with the Serum Institute of India (SII) to distribute its single-shot chikungunya vaccine across Asia, particularly in low-and-middle-income countries. This agreement is part of a $41.3 million funding initiative from the Coalition for Epidemic Preparedness Innovations (CEPI) and the European Union, aimed at addressing urgent public health needs amidst a severe chikungunya outbreak in India, where cases have surged to nearly 370,000 since 2019. Valneva will supply the vaccine's drug substance, while SII will handle manufacturing and regulatory approvals in the region. The commercialization will follow a profit-sharing model, supplemented by milestone payments to Valneva. This collaboration marks a significant step in enhancing regional health security and access to vaccination against a virus that has caused widespread outbreaks globally. The chikungunya vaccine is currently the only licensed vaccine for the virus, with ongoing regulatory reviews to expand its use to younger populations.